IMGN151 clinical trials
IMGN151 is named as an intervention in 2 current clinical trials in our USA, Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Australia, Japan and Israel registers. 1 is recruiting patients now. The most common phase is Phase 1. The lead sponsor is AbbVie. The most-studied condition is Fallopian Tube Cancer.
Patient leaflets for IMGN151
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of IMGN151
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784 · Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer
|
Phase 2 | Recruiting | AbbVie | USA, Japan, Israel |
|
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma
|
Phase 1 | Active, closed | AbbVie | Ireland, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with IMGN151
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about IMGN151 trials
How many clinical trials are testing IMGN151?
2 current trials in our USA, Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Australia, Japan and Israel registers name IMGN151 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are IMGN151 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in Japan and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors IMGN151 clinical trials?
The lead sponsor is AbbVie. The number in brackets is how many trials each organisation leads.
Are there IMGN151 clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IMGN151 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IMGN151 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IMGN151 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.